Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Closes $34.6M Public Offering

NEW YORK (GenomeWeb) – NeoGenomics today announced the closing of a public offering that raised $34.6 million in net proceeds.

The Ft. Myers, Fla.-based cancer genetic testing services firm offered 8.05 million shares at $4.60 per share, which included 1.05 million shares purchased by the underwriters on the offering as a result of the exercise of their overallotment option.

William Blair was the sole book-running manager, while Craig-Hallum Capital Group acted as co-lead manager. Stephens, Roth Capital Partners, Sidoti, and Dawson James were the co-managers.

NeoGenomics plans to use the proceeds for working capital, capital expenditures, and general corporate purposes, including potential acquisitions, and debt repayment, it said.

The Scan

Two J&J Doses

Johnson & Johnson says two doses of its SARS-CoV-2 vaccine provides increased protection against symptomatic COVID-19, CNN reports.

Pfizer-BioNTech Vaccine Response in Kids

The Pfizer-BioNTech SARS-CoV-2 vaccine in a lower-dose format appears to generate an immune response among children, according to the Washington Post.

Chicken Changes to Prevent Disease

The Guardian writes that researchers are looking at gene editing chickens to help prevent future pandemics.

PNAS Papers on Siberian Dog Ancestry, Insect Reproduction, Hippocampal Neurogenesis

In PNAS this week: ancestry and admixture among Siberian dogs, hormone role in fruit fly reproduction, and more.